Please assess the completion status of the following clinical trial:

Trial Title: Quetiapine Extended Release Depression Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of written informed consent~* Patients who satisfy the criteria for diagnosis of schizophrenia or schizoaffective disorder according to DSM-IVTR~* Baseline depressive symptoms, assessed by means of HAM-D (21-item) score ≥20, and HAM-D item 1 score ≥2~Exclusion Criteria:~* Any DSM-IV Axis I disorder other than schizophrenia and schizoaffective disorder~* Patients treated with depot antipsychotic medications within 1 dosing interval before day 0; patients treated with other AP oral medications during the trial except for the switch period~* Use of Clozapine within 28 days prior to enrollment or Clozapine non responders~* Any significant clinical disorder that, in the opinion of the investigator, made the subject unsuitable to be given treatment with an investigational drug~* An absolute neutrophil count (ANC) of ≤1.5 x 109 per liter~* Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Quetiapine Extended Release (Type: EXPERIMENTAL): None
- Risperidone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).